



Prostate Cancer: Molecular Imaging and Magnetic Resonance Imaging (MRI)

Guest Editors:

Dr. Marco Paciotti

1. Department of Urology, Humanitas Research Hospital, IRCCS, Rozzano, Milan, Italy
2. Onze Lieve Vrouw Hospital, Aalst, Belgium

Dr. Davide Maffei

1. Department of Urology, University College London Hospital NHS Foundation Trust, London, UK
2. Department of Biomedical Sciences, Humanitas University, Milan, Italy

Deadline for manuscript submissions:

16 May 2025

Message from the Guest Editors

Dear Colleagues,

Prostate cancer is the second most commonly diagnosed cancer in men worldwide. Magnetic resonance imaging (MRI) and molecular imaging have revolutionized the diagnostic–therapeutic pathway of prostate cancer. MRI has transformed prostate gland imaging, offering high-resolution anatomical details and functional information. Molecular imaging techniques, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), enable the visualization and characterization of specific molecular targets and metabolic processes associated with prostate cancer. The integration of molecular imaging and MRI holds great potential in improving the accuracy of prostate cancer diagnosis, risk stratification, and treatment planning, ultimately leading to more personalized approaches and improved patient outcomes. This Special Issue aims to shed light on the current state of molecular imaging and MRI for prostate cancer. By showcasing the latest research and advancements in this field, we strive to advance the field of molecular imaging and MRI for prostate cancer and pave the way for more precise and personalized approaches in its management.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)